Diabetic Neuropathy Market

The global Diabetic Neuropathy Market is valued at USD 4.7 Billion in 2024 and is projected to reach a value of USD 10.74 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 7.8% between 2025 and 2035.

Key Highlights

• The North American region predominantly led the market in 2024, with 38.5% of the total market share
• Europe is anticipated to witness the fastest growth from 2025 to 2035
• In 2024, the Peripheral Neuropathy segment took the lead in the market, contributing a 62.4% substantial revenue share
• The hospital pharmacies segment significantly contributed to the market’s expansion, constituting over 48.2% of the overall revenue share in 2024
• Cutting-edge medical devices, such as neuromodulation systems and wearable technologies, are gaining traction in neurotherapy. These devices offer non-invasive or minimally invasive options for managing neuropathy symptoms

Regional Overview

In 2024, North America accounted for 38.5% of the total revenue. Due to the large prevalence of diabetes and related neuropathy in this region, it holds an important share within the global healthcare landscape. There are a numerous therapies & treatments in the market, ranging from pharmaceutical products to novel devices that treat and alleviate symptoms of diabetic neuropathy. Also, strong healthcare infrastructure, advanced research facilities and high medical expenditure are contributing to the growth of the North American market. This region has been at the forefront of developing new therapies, including biologics and regenerative medicine, aiming to address the underlying causes of neuropathy. In addition, the presence of key pharmaceutical companies and a robust regulatory framework support ongoing research & clinical trials, fostering innovation in Diabetic Neuropathy.

U.S. Market Overview

The Diabetic Neuropathy market in the United States, with a valuation of USD 1.37 Billion in 2024, is projected to reach around USD 2.33 Billion by 2035. A significant Compound Annual Growth Rate (CAGR) of 6.1% from 2025 to 2035 is projected in this forecast. The U.S. Diabetic Neuropathy market is driven by the high incidence of diabetes and its complications, such as diabetic neuropathy. With a well-established healthcare infrastructure and major investment in R&D, the U.S. market is a hub for innovation. This market includes several treatments, from traditional pharmaceuticals to advanced medical devices designed to manage and alleviate neuropathic symptoms.

Disorder Type Overview

In 2024, the Peripheral Neuropathy category held a revenue share of 62.4%. The Disorder Type segment is divided into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, and Focal Neuropathy. Peripheral neuropathy is a major focus area as it addresses nerve damage common to diabetes. It is caused by damage to peripheral nerves, which can lead to symptoms such as tingling, numbness, pain, or weakness in the extremities. This condition affects a substantial portion of the diabetic population, driving the demand for effective treatments. Various treatments for managing symptoms and slowing the progression of neuropathy are included in this category, such as pain relievers and nerve-protective agents, as well as non-pharmacological approaches like physical therapy and electrical stimulation. The peripheral neuropathy category is expected to grow, with ongoing research focusing on innovative solutions that improve patient outcomes and quality of life, as diabetes prevalence continues to increase globally.

Distribution Channel Overview

In 2024, there was significant growth in the hospital pharmacies segment, over 48.2% of the market share. Based on the Distribution Channel, the market is segmented into Hospitals, Retail, and Online Pharmacies. Hospital pharmacies, serving as a primary source of medicines and treatments for diabetes neuropathy, play an important role in the worldwide market for Diabetic Neurotherapeutics. They are responsible for providing several treatments to patients with diabetes mellitus, such as pain management medications, anticoagulation drugs, and neuroprotection agents. To ensure that diabetic neuropathy treatment is tailored to individual patients needs, often requiring careful dosage adjustment and monitoring for side effects, hospital pharmacists work closely with healthcare professionals. In addition, they provide education on medication adherence and lifestyle changes to optimize therapeutic outcomes.

Key Trends

1. The development of advanced treatments such as biologics, stem cells, and regeneration therapy is changing the overall Diabetic Neuropathy landscape. These treatments provide a new method of treating nerve damage and supporting nerve regeneration, which can improve the patients outcome.
2. With the global increase in the diabetic population, theres a corresponding rise in diabetic neuropathy cases. This drives demand for Neurotherapy solutions, prompting further market growth and innovation.
3. With treatments tailored to individual patients based on genetic, lifestyle, and health profile factors, the shift towards personalized medicine affects the sector. This trend supports more effective and customized care.
4. Investment in research and development is on the rise, resulting in a pipeline of new treatments and an emphasis on dealing with the underlying causes of neuropathies. To meet the growing demand, companies are looking for novel compounds and treatment methods.
5. The sector is experiencing increased collaboration between pharmaceutical companies, biotech firms, and academic institutions. These partnerships support knowledge sharing, facilitate drug development, and accelerate the commercialization of new therapies.
6. Educating patients about diabetic neuropathy and its management is becoming increasingly important in addition to treatment. Healthcare providers & companies are developing resources and support programs to empower patients in managing their condition.

Premium Insights

The global diabetic neuropathy market is poised for major growth because of the increased occurrence of diabetes worldwide, with nearly 50% of people with diabetes experiencing some form of nerve damage. A range of symptoms, from mild tingling and numbness to severe pain & disability, can result from this nerve damage, which often affects the legs and feet. The demand for advanced neurotherapy solutions is driven by growing awareness of diabetic complications and an emphasis on early detection and management. To monitor blood sugar levels, the American Diabetes Association recommends regular glycated hemoglobin A1C tests, highlighting the importance of consistent glucose control in preventing or slowing diabetic neuropathy progression. The use of treatment strategies, along with lifestyle changes and personalized treatment plans, is becoming more popular, creating opportunities for innovative treatments and new entrants to the global market.

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point.

Market Dynamics

The growing incidence of diabetic neuropathy worldwide is seen as a key factor driving the market. The increasing number of older adults, the expansion of point-of-care services, rising healthcare expenditures, and other similar trends contribute to this market growth. This has led to a surge in research and development efforts aimed at introducing innovative drugs to treat neuropathic disorders. For example, Novartis AG has released Tegerton (carbamazepine), an anti-convulsant medication designed to alleviate neuropathic pain in diabetic patients by reducing the nerve impulses that cause pain. In addition, Janssen Pharmaceuticals has launched Nucynta ER, an opioid analgesic specifically for treating nerve damage related to diabetes.

Furthermore, innovative solutions like Abbotts newly FDA-approved Proclaim™ XR spinal cord stimulation (SCS) system, designed to treat painful diabetic peripheral neuropathy (DPN), a common and debilitating complication of diabetes propel the market outlook . Traditional treatments for DPN often rely on oral medications. Still, the Proclaim XR SCS system offers a non-opioid alternative that has been used for over 50 years to manage chronic pain. This system is especially promising given that approximately 50% of adults with diabetes develop peripheral neuropathy during their lifetime, experiencing symptoms such as pain, numbness, and tingling in the legs, feet, and hands.

Competitive Landscape

The market is growing, with rapid expansion fueled by innovation and technological progress. The sector also features a relatively high level of merger and acquisition (M&A) activity and collaborative efforts. Top companies in the global market include pharmaceutical giants like Pfizer, Novartis, and Eli Lilly, all of which are actively engaging in mergers and acquisitions to bolster their offerings in treatment devices and pharmaceuticals. Regulatory frameworks play a major role in shaping the diabetic neuropathy treatment industry, focusing on patient safety, encouraging innovation, and ensuring market competition. These regulations cover a range of activities, from drug approval processes and clinical trial requirements to post-marketing monitoring.

Recent Market Developments

Boehringer Ingelheims Breakthrough in Diabetic Macular Ischemia Treatment

• In May 2024, Boehringer Ingelheim shared promising results from the HORNBILL Phase I/IIa study of BI 764524, the pioneering study investigating a potential treatment for diabetic macular ischemia (DMI). The study revealed that BI 764524 was well tolerated after intravitreal administration in both single and multiple doses, achieving its primary safety goals and demonstrating initial signs of potential effectiveness.

NeuroMetrix Validates DPNCheck for Diabetic Peripheral Neuropathy Diagnosis

• In March 2024, NeuroMetrix Announces the Publication of a Study Confirming DPNChecks Accurate Diagnosis of Diabetic Peripheral Neuropathy. NeuroMetrix, Inc. (Nasdaq: NURO) reported the publication of a large-scale study showing that DPNCheck®, whether used with standard EKG or on its own, effectively detects diabetic peripheral neuropathy (DPN).

Astellas Pharmas Collaboration with Roche Diabetes Care Japan

• In March 2023, Astellas Pharma Inc. announced that it had signed an agreement with Roche Diabetes Care Japan Co., Ltd. (Country Manager: Noriko Hattori, "Roche Diabetes Care Japan") to develop and commercialize the globally recognized Accu-Chek® Guide Me blood glucose monitoring system with enhanced accuracy, integrated with BlueStar®*1. BlueStar is an FDA-approved digital health platform for diabetes patients, developed by Welldoc, Inc. (President, CEO: Kevin McRaith, "Welldoc"), and is currently available in the U.S. and Canada. Astellas and Welldoc are co-developing BlueStar in Japan, with Astell.

​

The global Diabetic Neuropathy market can be categorized as Disorder Type, Distribution Channel, and Region.